AZTA Stock - Azenta, Inc.
Unlock GoAI Insights for AZTA
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $593.82M | $656.32M | $665.07M | $555.50M | $513.70M |
| Gross Profit | $270.28M | $263.37M | $263.14M | $255.58M | $243.81M |
| Gross Margin | 45.5% | 40.1% | 39.6% | 46.0% | 47.5% |
| Operating Income | $24.46M | $-200,678,000 | $-73,126,000 | $-4,003,000 | $-46,547,000 |
| Net Income | $-59,503,000 | $-164,170,000 | $-14,257,000 | $-11,286,000 | $-28,869,000 |
| Net Margin | -10.0% | -25.0% | -2.1% | -2.0% | -5.6% |
| EPS | $-1.30 | $-3.09 | $-0.22 | $-0.15 | $-0.39 |
Azenta, Inc. provides life science sample exploration and management solutions for the life sciences market in North America, Europe, China, the Asia Pacific, and internationally. The company operates through two reportable segments, Life Sciences Products and Life Sciences Services. The Life Sciences Products segment offers automated cold sample management systems for compound and biological sample storage; equipment for sample preparation and handling; consumables; and instruments that help customers in managing samples throughout their research discovery and development workflows. The Life Sciences Services segment provides comprehensive sample management programs, integrated cold chain solutions, informatics, and sample-based laboratory services to advance scientific research and support drug development. This segment's services include sample storage, genomic sequencing, gene synthesis, laboratory processing, laboratory analysis, biospecimen procurement, and other support services. It serves a range of life science customers, including pharmaceutical companies, biotechnology companies, biorepositories, and research institutes. The company was formerly known as Brooks Automation, Inc. and changed its name to Azenta, Inc. in December 2021. Azenta, Inc. was founded in 1978 and is headquartered in Chelmsford, Massachusetts.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 19th 2025 | Needham | Reiterated | Buy | $44← $42 |
| October 30th 2025 | Jefferies | Upgrade | Buy | $38 |
| August 6th 2025 | Raymond James | Upgrade | Outperform | $35 |
| July 22nd 2025 | Stephens | Resumed | Equal Weight | $35 |
| December 18th 2024 | Stephens | Upgrade | Overweight | $60← $50 |
| April 4th 2024 | Jefferies | Initiation | Hold | $64 |
| February 1st 2024 | B. Riley Securities | Reiterated | Buy | $79← $61 |
| July 19th 2023 | Raymond James | Initiation | Market Perform | - |
| May 10th 2023 | KeyBanc Capital Markets | Downgrade | Sector Weight | - |
| February 9th 2023 | Stephens | Downgrade | Equal Weight | $60← $65 |
| January 3rd 2023 | Evercore ISI | Downgrade | In-line | $62← $60 |
Earnings History & Surprises
AZTAEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 5, 2026 | — | — | — | — |
Q1 2026 | Feb 4, 2026 | $0.11 | — | — | — |
Q4 2025 | Nov 21, 2025 | $0.19 | $0.21 | +10.8% | ✓ BEAT |
Q3 2025 | Aug 5, 2025 | $0.13 | $0.19 | +46.2% | ✓ BEAT |
Q2 2025 | May 7, 2025 | $0.09 | $0.05 | -44.4% | ✗ MISS |
Q1 2025 | Feb 5, 2025 | $0.05 | $0.08 | +60.0% | ✓ BEAT |
Q4 2024 | Nov 12, 2024 | $0.11 | $0.18 | +63.6% | ✓ BEAT |
Q3 2024 | Aug 6, 2024 | $0.07 | $0.16 | +128.6% | ✓ BEAT |
Q2 2024 | May 8, 2024 | $0.02 | $0.05 | +167.8% | ✓ BEAT |
Q1 2024 | Feb 7, 2024 | $0.01 | $0.02 | +159.7% | ✓ BEAT |
Q4 2023 | Nov 13, 2023 | $0.02 | $0.13 | +629.1% | ✓ BEAT |
Q3 2023 | Aug 8, 2023 | $0.02 | $0.13 | +714.0% | ✓ BEAT |
Q2 2023 | May 9, 2023 | $-0.05 | $-0.06 | -20.0% | ✗ MISS |
Q1 2023 | Feb 8, 2023 | $0.06 | $0.12 | +100.0% | ✓ BEAT |
Q4 2022 | Nov 14, 2022 | $0.06 | $0.16 | +166.7% | ✓ BEAT |
Q3 2022 | Aug 9, 2022 | $0.08 | $0.12 | +50.0% | ✓ BEAT |
Q2 2022 | May 9, 2022 | $0.11 | $0.12 | +9.1% | ✓ BEAT |
Q1 2022 | Feb 8, 2022 | $0.08 | $0.12 | +50.0% | ✓ BEAT |
Q4 2021 | Nov 10, 2021 | $0.77 | $0.78 | +1.3% | ✓ BEAT |
Q3 2021 | Aug 5, 2021 | $0.68 | $0.72 | +5.9% | ✓ BEAT |
Latest News
Needham Maintains Buy on Azenta, Raises Price Target to $44
📈 PositiveAzenta shares are trading higher after the company approved a $250 million share repurchase program.
📈 PositiveAzenta Approves $250M Share Repurchase Program
📈 PositiveAZTA stock has given up its prior loss. Azenta shares were trading lower after the company reported better-than-expected Q4 financial results.
📈 PositiveAzenta shares are trading lower after the company reported better-than-expected Q4 financial results.
➖ NeutralAzenta Q4 Adj. EPS $0.21 Beats $0.19 Estimate, Sales $159.000M Beat $156.150M Estimate
📈 PositiveAzenta Collaborates With PRECEDE Foundation To Offer Storage Of Study Samples In Biorepository And Streamline Logistics For Diagnostics, Patient Survival
📈 PositiveFrequently Asked Questions about AZTA
What is AZTA's current stock price?
What is the analyst price target for AZTA?
What sector is Azenta, Inc. in?
What is AZTA's market cap?
Does AZTA pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to AZTA for comparison